Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial

R. Dummer; D. E. Gyorki; J. Hyngstrom; A. C. Berger; R. Conry; L. Demidov; A. Sharma; S. A. Treichel; H. Radcliffe; K. S. Gorski; A. Anderson; E. Chan; M. Faries; M. I. Ross

doi:10.1038/s41591-021-01510-7

Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial

Nature Medicine ◽

10.1038/s41591-021-01510-7 ◽

2021 ◽

Vol 27 (10) ◽

pp. 1789-1796

Author(s):

R. Dummer ◽

D. E. Gyorki ◽

J. Hyngstrom ◽

A. C. Berger ◽

R. Conry ◽

...

Keyword(s):

Stage Iiib ◽

Phase 2 ◽

Talimogene Laherparepvec ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma

Annals of Oncology ◽

10.1093/annonc/mdw379.04 ◽

2016 ◽

Vol 27 ◽

pp. vi380 ◽

Cited By ~ 10

Author(s):

J. Chesney ◽

F. Collichio ◽

R.H.I. Andtbacka ◽

I. Puzanov ◽

J. Glaspy ◽

...

Keyword(s):

Stage Iiib ◽

Phase 2 ◽

Talimogene Laherparepvec ◽

Open Label ◽

Safety And Efficacy ◽

Phase 2 Study ◽

Open Label Phase

Download Full-text

Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.9508 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 9508-9508 ◽

Cited By ~ 18

Author(s):

Robert Hans Ingemar Andtbacka ◽

Reinhard Dummer ◽

David E. Gyorki ◽

Adam C. Berger ◽

Robert Martin Conry ◽

...

Keyword(s):

Interim Analysis ◽

Neoadjuvant Treatment ◽

Stage Iiib ◽

Phase 2 ◽

Talimogene Laherparepvec ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase

Download Full-text

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(20)30362-3 ◽

2021 ◽

Cited By ~ 2

Author(s):

Cornedine J de Gooijer ◽

Vincent van der Noort ◽

Jos A Stigt ◽

Paul Baas ◽

Bonne Biesma ◽

...

Keyword(s):

Malignant Mesothelioma ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Line Chemotherapy

Download Full-text

Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(21)00030-2 ◽

2021 ◽

Vol 8 (4) ◽

pp. e289-e298 ◽

Cited By ~ 1

Author(s):

Lu Sun ◽

Juan Wang ◽

Linlin Shao ◽

Chenglu Yuan ◽

Hongguo Zhao ◽

...

Keyword(s):

Immune Thrombocytopenia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Primary Immune Thrombocytopenia ◽

Open Label Phase ◽

Treatment Naïve

Download Full-text

Faculty Opinions recommendation of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739562946.793583755 ◽

2021 ◽

Author(s):

Patrick Richard

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

Open Label ◽

Phase 2 Trial ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

The Lancet ◽

10.1016/s0140-6736(14)61795-5 ◽

2015 ◽

Vol 385 (9973) ◽

pp. 1075-1086 ◽

Cited By ~ 208

Author(s):

Eric Lawitz ◽

Edward Gane ◽

Brian Pearlman ◽

Edward Tam ◽

Wayne Ghesquiere ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Efficacy And Safety ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Null Response

Download Full-text

Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(18)30480-8 ◽

2019 ◽

Vol 19 (1) ◽

pp. 46-55 ◽

Cited By ~ 9

Author(s):

Jung-Kyu Lee ◽

Ji Yeon Lee ◽

Deog Kyeom Kim ◽

Ho Il Yoon ◽

Ina Jeong ◽

...

Keyword(s):

Pulmonary Tuberculosis ◽

Phase 2 ◽

Open Label ◽

Intensive Phase ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(17)30170-9 ◽

2017 ◽

Vol 4 (10) ◽

pp. e487-e496 ◽

Cited By ~ 7

Author(s):

Fei-Er Feng ◽

Ru Feng ◽

Min Wang ◽

Jia-Min Zhang ◽

Hao Jiang ◽

...

Keyword(s):

Immune Thrombocytopenia ◽

Line Treatment ◽

Second Line ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Trans Retinoic Acid ◽

All Trans Retinoic Acid ◽

Primary Immune Thrombocytopenia ◽

Open Label Phase

Download Full-text

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70455-3 ◽

2014 ◽

Vol 15 (12) ◽

pp. 1311-1318 ◽

Cited By ~ 160

Author(s):

Nathan H Fowler ◽

R Eric Davis ◽

Seema Rawal ◽

Loretta Nastoupil ◽

Fredrick B Hagemeister ◽

...

Keyword(s):

Phase 2 ◽

Indolent Lymphoma ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text